Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.33 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266165 | 0.89 | MGLL (0.45) | PTGS2MGLLCCKARMALT1PIK3CD | |
| SCHEMBL5265920 | 0.88 | SCN9A (0.41) | SCN9ANTRK1P2RX7PTGS2MGLL | |
| SCHEMBL2917701 | 0.86 | NTRK1 (0.48) | SCN9ANTRK1PTGS2MGLLCCKAR | |
| SCHEMBL2913187 | 0.85 | NTRK1 (0.40) | SCN9ANTRK1P2RX7PTGS2MGLL | |
| SCHEMBL2918407 | 0.85 | CCKAR (0.41) | SCN9ANTRK1P2RX7PTGS2MGLL | |
| SCHEMBL5266147 | 0.85 | SCN9A (0.40) | SCN9ANTRK1P2RX7PTGS2MGLL | |
| SCHEMBL5271665 | 0.85 | NTRK1 (0.40) | SCN9ANTRK1P2RX7PTGS2MGLL | |
| SCHEMBL2918665 | 0.84 | MGLL (0.48) | SCN9ANTRK1PTGS2MGLLCCKAR | |
| SCHEMBL5267108 | 0.84 | PTGS2 (0.48) | PTGS2MGLLPIK3CDPIK3R2PIK3CA | |
| SCHEMBL5266199 | 0.83 | MGLL (0.42) | SCN9APTGS2MGLLMALT1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | SCN9A 1956/4885NTRK1 4691/4885P2RX7 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.